ANEBULO PHARMACEUTICALS, INC. (ANEB)

Import this data to Google Sheets with:

=jivedata("ANEB","financials")

Full statements spill as a table. For one cell: =jivedata("ANEB","Revenue") or =jivedata("ANEB","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

ANEBULO PHARMACEUTICALS, INC.

ANEB • CIK 0001815974

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Research and Development Expense	$5,600.197	$3,548.937	$4,299.941	$3,739.275
General and Administrative Expense	$6,183.402	$4,759.818	$4,923.54	$5,364.101
Operating Expenses	$11,783.599	$8,308.755	$9,223.481	$9,103.376
Operating Income (Loss)	$-11,783.599	$-8,308.755	$-9,223.481	$-9,103.376
Net Income (Loss) Attributable to Parent	$-11,732.338	$-8,201.703	$-8,484.763	$-7,978.748
Weighted Average Number of Shares Outstanding, Basic	25,074,481	25,822,258	33,820,306	48,230,713
InterestExpenseNonoperating	—	$151.23	$382.014	$297.499
Interest Income, Other	$92.407	$249.022	$257.913	$419.866
Other Nonoperating Income (Expense)	$-41.146	$9.26	$-1.195	$-1.089
Nonoperating Income (Expense)	$51.261	$107.052	$738.718	$1,124.628
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	4,313,963	4,583,698	5,482,905	6,127,679

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Cash and Cash Equivalents, at Carrying Value	—	$3,094.2	$11,627.849	$9,041.57
Assets, Current	—	$3,507.99	$11,962.506	$9,273.766
Prepaid Expense, Current	$422.748	$413.79	$261.439	$175.413
Assets	$11,670.151	$4,073.114	$12,145.616	$9,421.997
Liabilities	$1,068.801	$260.583	$487.688	$1,485.646
Other Assets, Noncurrent	—	$565.124	$183.11	$148.231
Accounts Payable, Current	$534.545	$156.426	$224.175	$554.862
Accrued Liabilities, Current	$534.256	$104.157	$263.513	$930.784
Common Stock, Value, Issued	$25.634	$25.934	$41.086	$41.086
Additional Paid in Capital	$67,777.757	$69,190.341	$85,505.349	$85,941.523
Retained Earnings (Accumulated Deficit)	$-57,202.041	$-65,403.744	$-73,888.507	$-78,046.258
Stockholders' Equity Attributable to Parent	$10,601.35	$3,812.531	$11,657.928	$7,936.351
Preferred Stock, Shares Authorized	2,000,000	2,000,000	2,000,000	2,000,000
Preferred Stock, Shares Issued	0	0	0	0
Common Stock, Shares Authorized	40,000,000	50,000,000	75,000,000	75,000,000
Common Stock, Shares, Issued	25,633,217	25,933,217	41,084,731	41,084,731

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Net Income (Loss) Attributable to Parent	$-11,732.338	$-8,201.703	$-8,484.763	$-7,978.748
Net Cash Provided by (Used in) Operating Activities	$-9,683.133	$-8,090.849	$-6,349.687	$-5,840.233
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$-3,301.068	$-8,153.203	$8,533.649	$-5,956.897
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations	$11,247.403	$3,094.2	$11,627.849	$20,578.411
Share-based Payment Arrangement, Noncash Expense	$884.723	$758.884	$1,446.824	$1,031.745
Proceeds from Issuance of Common Stock	$6,646.748	$6,646.748	$15,000	$15,000
Amortization of Debt Issuance Costs	—	$151.23	$382.014	$297.5
Payments of Financing Costs	—	—	$116.664	$116.664
Net Cash Provided by (Used in) Financing Activities	$6,382.065	$-62.354	$14,883.336	$14,883.336
Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction	—	$654	$654	$654
Increase (Decrease) in Prepaid Expense	$-608.212	$-8.958	$-152.351	$-190.853
Increase (Decrease) in Accounts Payable	$153.717	$-378.119	$67.749	$272.944
Increase (Decrease) in Accrued Liabilities	$402.553	$-430.099	$159.356	$371.5

Loading financial statements…

Import this data to Google Sheets with:

=jivedata("ANEB","financials")

Full statements spill as a table. For one cell: =jivedata("ANEB","Revenue") or =jivedata("ANEB","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.